KIT and gastrointestinal stromal tumor: Here, we observed that nintedanib can overcome imatinib resistance induced by cKIT secondary mutations and elevated FGF ligand expression, thus providing a new potential therapy for patients with GIST that acquired resistance to Imatinib.